Gilead Sciences Inc. closed 10.06% short of its 52-week high of $119.96, which the company achieved on March 10th.

Shares of UNITY Biotechnology UBX crashed 28.8% yesterday, following mixed results from a mid-stage non-inferiority study of ...

NORTHAMPTON, MA / ACCESS Newswire / March 25, 2025 / HIV infection and lung cancer have little in common from a disease ...

Nidhi Shashikumar is a data scientist and business intelligence expert with over 7 years of experience in healthcare ...

GENEVA: The world risks returning to the worst days of the global AIDS pandemic following the sudden halt to US foreign aid ...

In the latest trading session, Gilead Sciences (GILD) closed at $106.67, marking a -0.38% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 1.77% for the day.

Geneva: The global fight against AIDS faces a severe setback following the abrupt halt of US foreign aid funding, the UN's ...

The world risks returning to the worst days of the global AIDS pandemic following the sudden halt to US foreign aid funding, ...

Winnie Byanyima, head of UNAIDS, criticized the impact of reduced U.S. funding in combatting HIV. She proposed a deal to U.S.

Monumental Sports & Entertainment has tapped Starbucks Corp.’s chief corporate affairs officer to lead its communications.

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $90.00.